Adrian R. Krainer, Director at Stoke Therapeutics, Inc. (STOK), sold 7,229 shares at $39.66 ($287K) on 2026-03-02, disclosed to the SEC on 2026-03-04.
Scheduled sale ($287k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| STOK | SELL | 2025-11-18 | $2.2M | — | Filing → |